Rapid Evidence Synthesis: Senolytics May Backfire in Advanced Plaques

Researka accepted publication: b18dacf3-a86e-4d0d-b54f-ea476005c515 Source submission: 8516a3db-9b7c-4e7c-8e1a-10fa96440733 A source-grounded submission for Researka review. Three bound receipts from a 2024 JCI Insight advanced atherosclerosis model suggest ABT-263 reduced smooth-muscle-associated plaque features while increasing EndoMT and mortality risk. The claim is intentionally narrow and preclinical.